A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Smoking

In brief

This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period.

Key facts

Study ID
NCT07223840
Run by
Eli Lilly and Company
People needed
222
Starts
2025-11-03
Expected to finish
2027-02-01
Last updated by the study team
2026-08-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.